A carregar...
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
BACKGROUND: Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. CASE PRESE...
Na minha lista:
| Publicado no: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5804097/ https://ncbi.nlm.nih.gov/pubmed/29445583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0096-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|